Beta Bionics, Inc. BBNX
Set alert
15.90 USD -0.85 -5.07%
At close · Nov 2
15.90 0.00 0.00%
After hours · Nov 2, 4:26 PM ET
15.87 Day range 17.30
8.80 52-week range 32.71
- YTD
- -47.82%
- 1 year
- -41.59%
- Open
- 16.90
- Prev close
- 16.75
- Mkt cap
- 864.44M
- Vol
- 804.22K
- Avg vol
- 1.28M
- EPS
- -1.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.87
- High
- 17.30
- Forward P/E
- -9.90
- Beta
- 0.00
- Short ratio
- 4.12
- Inst. own
- 112.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 16, 2027
- 50-d avg
- 19.16
- 200-d avg
- 14.81
- 1y target
- 24.24
Key statistics
- Market cap
- 1.15B
- Enterprise value
- 748.76M
- Trailing P/E
- 0.00
- Forward P/E
- -9.90
- PEG ratio
- 0.00
- Price / sales
- 9.70
- Price / book
- 3.75
- EPS (TTM)
- -1.76
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -61.31%
- Revenue (TTM)
- 119.01M
- Revenue growth
- 37.80%
- Free cash flow
- -40.29M
- Total cash
- 180.49M
- Total debt
- 6.51M
- Return on equity
- -26.16%
- Shares outstanding
- 53.95M
- Short % of float
- 11.25%
- 50-day average
- 19.16
- 200-day average
- 14.81
Analyst view
Consensus: none
Price target (mean) 24.24 +52.5% upside
Now 15.90
- Target (low)
- 16.00
- Target (mean)
- 24.24
- Target (high)
- 30.40
Ratings (0m) 15 11 buy · 4 hold · 0 sell
- Strong buy2
- Buy9
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate -0.51333.
Financials — quick view
BBNX Revenue — quarterly 35.51M
BBNX Net income — quarterly -24.35M
BBNX EPS — quarterly -0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | -0.49 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | -0.52334 | -0.52 | 0.00 | +0.64% |
| Jul 29, 2026 | Jun 30, 2026 | -0.58103 | -0.53 | +0.05 | +8.78% |
| Apr 21, 2026 | Mar 31, 2026 | -0.53 | -0.49 | +0.04 | +7.55% |
| Feb 17, 2026 | Dec 31, 2025 | -0.42 | -0.30 | +0.12 | +28.57% |
| Oct 28, 2025 | Sep 30, 2025 | -0.45 | -0.33 | +0.12 | +26.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | init | — | Buy |
| Sep 24, 2026 | Truist Securities | main | Buy | Buy |
| Sep 23, 2026 | Wells Fargo | init | — | Overweight |
| Sep 15, 2026 | B of A Securities | main | Neutral | Neutral |
| Sep 15, 2026 | Truist Securities | reit | Buy | Buy |
| Sep 15, 2026 | Baird | main | Neutral | Neutral |
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- betabionics.com
News
- BBNX FINAL DEADLINE ALERT: Beta Bionics Investors with Losses Encouraged to Contact Hagens Berman Before Nov. 3rd Deadline in Securities Class Action
- INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
- DEADLINE ALERT for DICK'S Sporting Goods, Inc. (DKS), Beta Bionics, Inc. (BBNX), Better Home & Finance Holding Company (BETR), and Coastal Financial Corporation (CCB): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
- Deadline Alert: Beta Bionics, Inc. Investors Have Until November 3, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors
- Kaplan Fox Reminds Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Approaching Securities Class Action Deadline on November 3, 2026
- DEADLINE ALERT for DICK'S Sporting Goods, Inc. (DKS), Beta Bionics, Inc. (BBNX), FuelCell Energy, Inc. (FCEL), and Lincoln Educational Services Corp. (LINC),: The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
- Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 3, 2026 - BBNX
- BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
- DEADLINE TOMORROW: Berger Montague Advises Beta Bionics, Inc. (BBNX) Investors to Inquire About a Securities Fraud Class Action by November 3, 2026
- Kaplan Fox Reminds Investors of Beta Bionics, Inc. (BBNX) of the Deadline to Seek Lead Plaintiff Status on November 3, 2026
Your note
Sign in to keep a note on BBNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARNEY SEAN D | Director | Stock Award(Grant) | May 20, 2026 | 32,209 |
| DEAREN DANNY L | Director | Stock Award(Grant) | May 20, 2026 | 32,209 |
| FEIDER STEPHEN | Chief Financial Officer | Sale | Sep 1, 2026 | 159,378 |
| HOPMAN MARK | Officer | Sale | Sep 30, 2026 | 56,109 |
| MENSINGER MIKE | Officer | Sale | Sep 15, 2026 | 177,390 |
| MICHEL GERARD J | Director | Stock Award(Grant) | May 20, 2026 | 33,509 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eventide Asset Management LLC | 13.90% | 6,253,673 | 133.77M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 9.77% | 4,393,714 | 93.98M | Jun 29, 2026 |
| Morgan Stanley | 9.48% | 4,266,822 | 91.27M | Jun 29, 2026 |
| Sands Capital Alternatives, LLC | 8.24% | 3,708,043 | 79.32M | Jun 29, 2026 |
| Blackrock Inc. | 7.42% | 3,340,171 | 71.45M | Jun 29, 2026 |
| Point72 Asset Management, L.P. | 5.01% | 2,254,683 | 48.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 8.86% | 3,983,917 | 85.22M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 4.56% | 2,052,176 | 43.90M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.83% | 1,272,504 | 27.22M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.35% | 1,055,217 | 22.57M | Sep 29, 2026 |
| Bruce Fund, Inc.-BRUCE FUND | 1.48% | 665,700 | 14.24M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.04% | 469,615 | 10.05M | Jun 29, 2026 |